Aucubin promoted neuron functional recovery by suppressing inflammation and neuronal apoptosis in a spinal cord injury model

Shining Xiao, Nanshan Zhong, Quanming Yang, Anan Li, Weilai Tong, Yu Zhang, Geliang Yao, Shijiang Wang, Jiaming Liu, Zhili Liu

Abstract

Spinal cord injury (SCI) often results in severe and permanent motor impairment. Current therapeutic strategies focus on mitigating the "secondary injury" phase, characterized by neuroinflammation and neuronal apoptosis. This study investigates the therapeutic potential of Aucubin (Au), a natural iridoid glycoside, in a rat model of SCI. We demonstrate that Aucubin promotes functional recovery by suppressing the TLR4/NF-κB signaling pathway, thereby encouraging M2 microglial polarization and inhibiting mitochondrial-mediated apoptosis. These effects reduce tissue damage and facilitate axonal regeneration, positioning Aucubin as a promising candidate for post-SCI treatment.

Introduction

Spinal cord injury (SCI) is a devastating condition with limited clinical interventions. The pathology is divided into a primary mechanical injury followed by a secondary injury cascade. This secondary phase involves a wave of neuroinflammation, oxidative stress, and programmed cell death (apoptosis) that significantly expands the initial lesion.

A key driver of this damage is the behavior of microglia, the resident immune cells of the central nervous system. Following injury, microglia typically adopt a pro-inflammatory "M1" phenotype that exacerbates tissue loss. Shifting these cells toward an anti-inflammatory, pro-repair "M2" phenotype is a major goal in neurotrauma research. Aucubin, a compound derived from traditional herbal medicine, has shown anti-inflammatory properties in other contexts, but its efficacy in SCI has not been previously established.

Methods

The researchers employed a comprehensive experimental design using both animal and cellular models:

  • In Vivo Model: Sprague-Dawley rats underwent a T9 spinal cord compression injury. The treatment group received daily intraperitoneal injections of Aucubin (40 mg/kg), while control groups included a Sham group (surgery without injury) and an untreated SCI group.
  • In Vitro Models: BV2 microglia were stimulated with LPS to model neuroinflammation, and PC12 cells were treated with TBHP to model oxidative stress-induced apoptosis.
  • Evaluation: Motor recovery was tracked over 28 days using the Basso, Beattie, and Bresnahan (BBB) scale and footprint analysis. Histological changes were assessed via H&E staining to measure lesion cavity size. Molecular mechanisms were explored using Western blotting, immunofluorescence, and TUNEL assays to track protein expression and cell death.

Results

Improved Locomotor Recovery and Reduced Tissue Damage

Aucubin treatment led to a significant improvement in motor function. By day 28 post-injury, rats treated with Aucubin achieved a mean BBB score of approximately 12, indicating consistent weight-supported stepping. In contrast, the untreated SCI group scored approximately 6, representing only slight joint movement. Footprint analysis confirmed these results, showing more coordinated gait patterns in the Aucubin group.

Histological analysis revealed that Aucubin significantly preserved spinal cord architecture. The size of the cystic cavities—areas of permanent tissue loss—was markedly smaller in the treated rats compared to the untreated controls.

Figure 1: Aucubin treatment improves motor function and reduces spinal cord lesion size in a rat model of SCI.

Modulation of Inflammation and Apoptosis

Molecular analysis indicated that Aucubin acts as a potent immunomodulator. It suppressed the TLR4/MyD88/NF-κB signaling pathway, which is the "master switch" for the inflammatory response. This inhibition resulted in a shift from the damaging M1 microglial phenotype to the regenerative M2 phenotype, evidenced by a reduction in pro-inflammatory markers like iNOS and COX-2.

Furthermore, Aucubin protected neurons from apoptosis by stabilizing mitochondrial function. It balanced the expression of Bcl-2 (anti-apoptotic) and Bax (pro-apoptotic) proteins, leading to a dramatic decrease in TUNEL-positive (dying) cells. This neuroprotection was accompanied by increased levels of MAP2 and GAP43, proteins associated with axonal growth and structural repair.

Discussion and Conclusion

The study provides robust evidence that Aucubin mitigates secondary spinal cord injury through a multi-targeted approach. By simultaneously suppressing neuroinflammation and preventing neuronal apoptosis, Aucubin creates a more permissive environment for spinal cord repair. The transition of microglia to an M2 state is particularly critical, as it shifts the local environment from one of destruction to one of regeneration.

While these results are promising, limitations remain. The specific cellular receptors that bind Aucubin are not yet identified, and the long-term safety of chronic administration requires further study. Nevertheless, Aucubin represents a potential new therapeutic avenue for improving the quality of life for patients suffering from spinal cord injuries.

Summary updated

BibTeX
@inproceedings{xiao2022aucubin,
  author = {Shining Xiao and Nanshan Zhong and Quanming Yang and Anan Li and Weilai Tong and Yu Zhang and Geliang Yao and Shijiang Wang and Jiaming Liu and Zhili Liu},
  title = {{Aucubin promoted neuron functional recovery by suppressing inflammation and neuronal apoptosis in a spinal cord injury model}},
  booktitle = {Research},
  year = {2022},
  doi = {10.21203/rs.3.rs-1342741/v1},
}
Figure